Michael Brown | Colliers International | Jacksonville

Michael Brown

Senior Director, Office Services

License # SL3412270

Call Michael
View More View Less

About

Professional Summary

As the National Leader of Colliers Global Life Science Practice Group, I bring 43 years of commercial real estate experience and 22 years of experience focusing on life science real estate. My acquired knowledge in life science work has been on both the landlord (Wexford Science & Technology) and the tenant side within the industry.

I have experience with Advanced Therapeutic Medicinal Products, Parenteral Fill Finish, Solid Oral Dosage, Biologics, and Medical Device manufacturing facilities, as well as a solid background in Laboratory Research and Development/Pilot scale facilities and controlled environments. Through my work on local, regional and national site selection assignments, I have developed a firm grasp of the rigorous process required to meet the key search criteria of my clients.  

My knowledge of market conditions and influences in the life sciences supports my ability to be creative in structuring the financial details of both lease and purchase transactions. My network of a wide variety of trusted advisors within the industry facilitates a regular flow of information about life science real estate trends, pricing, and comparable data for leasing and sales transactions.

Accomplishments

Sold and  Leased Over 13,000,000 SF of Life Science Facilities 

Currently leading a group of 42 highly qualified professionals  who are focused on life science real estate sales, leasing and consulting across the US

 

Education

BA | English
LaSalle University

Memberships & Involvements

BioFlorida

Clients

Ancora, Cellectis SA, Alexandria Real Estate; ALMAC Clinical Services; Assembly Bio; BioMed Realty Trust; Cellectis SA; The Science Center of Philadelphia; University of Pennsylvania; Spirovant, Wexford Science & Technology

Services

Skills
Life Sciences, Development Consulting, Project Leasing, Technology Services
Service Lines
Landlord Representation, Tenant Representation
Property Type
Healthcare-Medical
Specializations
Life Sciences Group

My Team

My Team

Featured Research
Jun 24, 2020
Mid-Year Update: COVID-19 Impact on the Life Sciences Real Estate Sector
Lab productivity is recovering. COVID-related investigations are on a fast track. Expansion requirements are back on pace, even exceeding pre-COVID levels.
Read More
Mar 24, 2020
SARS-CoV-2 Impact on the Life Sciences Real Estate Sector
Learn the five trends facing the lab real estate sector as we react to a global pandemic in a new Colliers Life Sciences whitepaper report.
Read More
Feb 25, 2020
In-House or Outsource? Considerations for Biotechs at the Drug Manufacturing Crossroads
In house or outsource to a CDMO? Five considerations for pre-clinical and clinical drug development companies facing critical manufacturing decisions, authored by Joseph Fetterman of the Colliers Life Sciences Practice Group.
Read More
View More
Featured News
Apr 1, 2020
North Florida is predicted to become a Life Sciences Cluster
Continued development around the University of Florida, Alachua County, and the Mayo Clinic in Jacksonville provide a good foundation for North Florida to become a small life sciences cluster, deems Colliers' life sciences commercial real estate expert, Michael J. Brown.
Read More
Mar 19, 2020
Coronavirus as a Catalyst: How COVID-19 Could Impact Life Science CRE
COVID-19 has impacted virtually every industry, and commercial real estate is no exception. For the life science branch of CRE, the coronavirus could serve as a powerful catalyst that brings increased demand to an already-tight market.
Read More
Mar 19, 2019
UCART Manufacturing Facility Site Selection
We structured a lease for Cellectis, a Paris based clinical-stage biopharmaceutical company, to create an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Read More
Mar 13, 2019
Colliers International Concludes 82,985 SF Lease for New UCART Manufacturing Facility in Raleigh, North Carolina
Cellectis, a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells, has announced that it has entered into a lease agreement for an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Read More
View More

How can I help you?

An unexpected error has occurred. Please try again.
Your request has been submitted.
Someone will contact you shortly.